Reps. Tulsi Gabbard (HI-02) and Carlos Curbelo (FL-26) led a group of bipartisan lawmakers in introducing The Marijuana Data Collection Act. The act calls upon the National Academy of Sciences (NAS) to collect and synthesize relevant data and to generate a formal report to Congress quantifying the impact of statewide marijuana legalization on matters specific to public health, safety, the economy, and criminal justice, among other issues.
Even though recreational marijuana remains criminalized in a majority of US states, more and more municipalities are moving ahead with local laws decriminalizing the possession of cannabis within city limits. For the first time, NORML has released a comprehensive breakdown of these citywide and countywide decriminalization policies.
United States Rep. Timothy Waltz (D-MN), along with over 30 bipartisan co-sponsors, has introduced legislation, HR 5520: The VA Medicinal Cannabis Research Act of 2018, to facilitate federally-sponsored clinical research into the safety and efficacy of medical cannabis among veterans.
Members of Congress this week heard testimony on the state of marijuana research, and leading members of the US Senate introduced legislation to potentially reclassify CBD. A medical marijuana initiative in Montana qualified for the November ballot and Governors in three states signed marijuana related bills into law. Click here to get this week’s latest marijuana news and to find out how you can #TakeAction.
This has been an exceptionally busy week at the state and federal level for marijuana law reform. Click below to get the latest news and to find out how you can #TakeAction.
Federal lawmakers pressured President Obama this week to take executive action to reform marijuana policy. Meanwhile, state legislative reforms are still moving forward throughout the country. Click here to get the latest news and to learn what you can do to take action.
Massachusetts Senator Elizabeth Warren, along with seven other Senators, has directed a letter to the Obama administration demanding regulators answer questions specific to the facilitation of research into the medical benefits of marijuana.
Members of the US Senate at a hearing yesterday expressed skepticism in regard to federal policies limiting the ability of investigators to engage in clinical studies of marijuana’s health benefits. Senators heard from representatives from the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA), University of Mississippi Medical Center, Arrowhead Regional Medical Center and Project SAM on a variety of issues The hearing’s most noteworthy moment came when Nora Volkow, director of NIDA, acknowledged that the monopoly on marijuana cultivation for research purposes […]
It bears repeating that ample scientific research already exists to contradict cannabis’ federal, schedule I status as a substance without medical utility, lacking acceptable safety, and possessing a high potential of abuse. More clinical research is welcome, but unfortunately science has never driven marijuana policy. If it did, the United States would already have a very different policy in place.
While the US government effectively bans scientific research regarding cannabis and any potential therapeutic uses, you can help University of Texas at Dallas associate professor of Criminology Dr. Robert Morris, II conduct another in a series of cannabis policy research-related questions. Dr. Morris and associates have already published an interesting research article earlier this year at PLoS One, answering the question: Does Legalizing Medical Cannabis Reduce Violent Crimes?* This time around Dr. Morris and his colleagues are asking the sensible question public policy question: ‘Does Medical Cannabis Legalization Impact Police […]